Refining risk stratification of patients with early breast cancer eligible for adjuvant abemaciclib or ribociclib.

Kisqali (ribociclib) - Novartis

Verzenio (abemaciclib) - Eli Lilly

http://www.ncbi.nlm.nih.gov/pubmed/42599204

Eva Blondeaux; Evandro de Azambuja; Luca Arecco; Lucia Del Mastro; Marco Bruzzone; Matteo Lambertini

Aug 15, 2026